CBER and EMA CAT for Cell Therapy — Regulatory Differences That Demand a Dual-Region Strategy

A cell therapy CMC package built for CBER will satisfy many EMA requirements — and fail specific ones. Discovering which ones at pre-submission costs less than discovering them at Day 180 of a CAT review.

The statutory frameworks governing cell therapy in the United States and European Union are not parallel systems converging on the same destination — they are distinct regulatory architectures built on different legal foundations, enforced by different agencies with different review philosophies, and operationalized through CMC requirements that diverge at precisely the points where cell therapy development is most technically complex. For programs pursuing both FDA approval and EMA authorization, the instinct to build one CMC package and adapt it bilaterally is reasonable but dangerous. The question is not whether your CBER package and your EMA dossier will overlap — they will. The question is which jurisdiction-specific requirements your overlap strategy will miss, and how much it will cost you when the Committee for Advanced Therapies identifies them at clinical trial authorization review.

The CBER Review Framework for Cell Therapy: How It Differs From EMA CAT

CBER’s Office of Therapeutic Products (OTP, formerly the Office of Tissues and Advanced Therapies) reviews cell therapy products under a framework anchored in 21 CFR Part 1271, which establishes donor eligibility, current Good Tissue Practice, and the manufacturing controls required for human cells, tissues, and cellular and tissue-based products. For cell therapy products meeting the definition of a biologic under the Public Health Service Act, CBER review proceeds through the IND/BLA pathway, with CMC requirements shaped by a series of guidance documents — including FDA’s Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products (finalized June 2015) — that acknowledge the unique challenges of characterizing a living, patient-derived or donor-derived drug substance. The CBER review model centers on a manufacturing process description that demonstrates process control at each critical step, a lot release specification package grounded in identity, purity, potency, viability, and safety testing, and a comparability framework that can accommodate the manufacturing changes that inevitably occur between Phase 1 and BLA submission.

What distinguishes the CBER framework in practice is the expectation that the IND CMC package will mature progressively, with CBER-specific precedents — established through pre-IND and Type B meetings — guiding the development of potency assays, comparability protocols, and release specification tiers. A CAR-T product developed under CBER jurisdiction will accumulate an IND history that includes CMC information amendments, manufacturing hold notifications, and agency feedback on analytical method development — all of which inform the BLA package but are not directly transferable to the EMA CAT review context, where the dossier is evaluated against EU Regulation 1394/2007 on ATMPs and the technical requirements embedded in EMA/CAT guidance without the benefit of that pre-submission dialogue.

The EMA CAT ATMP Dossier Requirements for Cell Therapy: Key CMC Differences From a BLA

EU Regulation 1394/2007 established the legal classification framework for Advanced Therapy Medicinal Products — somatic cell therapy medicinal products, tissue-engineered products, and gene therapy medicinal products — and assigned primary scientific evaluation authority to the Committee for Advanced Therapies. The CMC documentation requirements that flow from this regulation and its implementing guidance differ from CBER’s BLA CMC requirements in several technically significant ways. The most consequential is starting material documentation: EU Annex I Part IV of Directive 2001/83/EC as amended by Regulation 1394/2007 requires that the dossier include detailed documentation of starting material procurement, donor testing, and traceability specifically in the format and to the standard defined under EU law. A company that has built its starting material documentation entirely around 21 CFR Part 1271 donor eligibility requirements will find that the EU Directive 2004/23/EC standards for human tissue and cell procurement — covering donor consent, donor testing panels, and traceability to the tissue establishment — impose requirements that are not automatically satisfied by FDA-compliant documentation.

The traceability obligation under EU law extends to a 30-year retention requirement for records linking the starting material to the final medicinal product — a requirement that is explicit under the ATMP framework and must be addressed in the quality system description within the MAA dossier. Programs that have documented their chain-of-identity system for US regulatory purposes often address CBER’s traceability expectations — lot number linkage, leukapheresis record retention, chain-of-custody documentation — without explicitly confirming that the 30-year EU standard is embedded in the system design. The European Commission’s “Guidelines on Good Manufacturing Practice specific to Advanced Therapy Medicinal Products” (EudraLex Volume 4, Part IV — adopted November 2017, mandatory since May 2018) also imposes GMP standards that are not identical to FDA 21 CFR Part 211 and 21 CFR Part 1271 as applied by CBER — and a program that has not conducted an explicit Part IV gap assessment against its manufacturing site’s quality system will arrive at clinical trial authorization in the EU without having confirmed that its GMP documentation satisfies the applicable EU standard.

The European Pharmacopoeia monographs applicable to ATMPs add a further layer of compendial requirements that have no precise FDA equivalent. Where CBER accepts in-house methods validated according to ICH Q2(R2) without a compendial anchor, EMA expects that Ph. Eur. monographs are either met or that the dossier includes a scientifically justified deviation. For identity and purity testing of cell therapy starting materials — particularly donor-derived leukocyte populations characterized by flow cytometry using CD marker panels consistent with ISCT criteria — the Ph. Eur. framework provides reference points that must be addressed explicitly in the analytical section of the Module 3 equivalent within the IMPD or MAA.

Dual-Region Cell Therapy CMC Strategy: The Points of Alignment and Where Requirements Diverge

The points of true alignment between CBER and EMA CAT for cell therapy CMC are real and operationally significant: both agencies accept the ICH Q5 series (and ICH Q2(R2), the current validation of analytical procedures guideline) as applicable to cell therapy where the product meets the relevant scope definitions; both expect a potency assay that reflects the product’s mechanism of action — for a CAR-T product, that means demonstrating antigen-specific cytolytic activity or cytokine release (IFN-γ, IL-2, TNF-α) in a qualified cell-based assay, not a surrogate biochemical readout; both expect stability data supporting the proposed shelf life under cryopreservation conditions, including DMSO concentration documentation in the cryopreservation formulation; and both expect a comparability framework that bridges manufacturing changes to the clinical dataset. These harmonized expectations are the foundation of a dual-region strategy, but they do not eliminate the jurisdiction-specific requirements that a bilateral program must address independently.

The divergence points that most frequently generate Day 180 CAT deficiencies are precisely the ones that are structural rather than analytical: ATMP classification not confirmed with EMA before the clinical trial application is filed; GMP standard applied to the manufacturing site assessed only under FDA 21 CFR rather than EU GMP Annex 2A for ATMPs; donor testing panel documented according to 21 CFR Part 1271 without an explicit assessment against EU Directive 2004/23/EC requirements; and the 30-year traceability system designed and documented for US regulatory purposes only. None of these failures reflect deficiencies in cell therapy science or manufacturing — they reflect the common and correctable error of treating a bilateral submission as a translation exercise rather than a dual-system compliance exercise. For a CAR-T program using a lentiviral vector incorporating a ΔWPRE element to remove hepatitis B X protein sequences — a safety design decision with CMC implications in both jurisdictions — the documentation requirements around the safety rationale, the specific deletion confirmation method, and the residual risk assessment will be reviewed through different evidentiary frameworks by CBER and EMA CAT, and both must be addressed in their respective regulatory language.

FDA’s Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products (2015) provides CBER’s early-phase CMC framework for cell therapy, but it does not map onto EMA’s Guideline on Human Cell-Based Medicinal Products (EMEA/CHMP/410869/2006), which reflects EU-specific requirements including the ATMP classification system, the IMPD format, and EU-specific manufacturing authorization requirements. A dual-region CMC strategy must treat these as parallel frameworks to be satisfied independently — not as one framework with regional footnotes.

Building a Cell Therapy CMC Dossier That Satisfies Both CBER and EMA CAT Without Duplicate Programs

The XGene Cell Therapy Dual-Region CMC Gap Assessment is a structured, side-by-side evaluation of CBER and EMA CAT CMC requirements for cell therapy programs planning bilateral submissions — designed to identify jurisdiction-specific requirements, confirm harmonized ICH elements, assess hospital exemption considerations where relevant, and produce a gap-analysis deliverable that drives submission-ready documentation from IND/CTA through BLA/MAA.

Step 1 — Statutory and Classification Mapping: Confirm the product’s regulatory classification under both FDA (21 CFR Part 1271 HCT/P analysis and biologic determination) and EU Regulation 1394/2007 ATMP classification — somatic cell therapy, tissue-engineered product, or combined ATMP — and verify that EMA ATMP classification has been confirmed prior to clinical trial authorization filing, because a misclassified product reaches Day 180 of CAT review before the classification error surfaces.

Step 2 — Starting Material Documentation Gap Analysis: Conduct a line-by-line comparison of the existing starting material documentation package against EU Annex I Part IV requirements and EU Directive 2004/23/EC donor testing standards — specifically confirming that the donor testing panel, consent documentation, and tissue establishment qualification records satisfy the EU framework independently of their FDA compliance status, and that the traceability system explicitly addresses the 30-year EU retention requirement in its quality system documentation.

Step 3 — GMP Standard Assessment: Evaluate the manufacturing site’s quality system and GMP documentation against EudraLex Volume 4, Part IV (GMP specific to ATMPs) as the applicable standard — distinct from the FDA 21 CFR assessment already completed — identifying gaps in personnel qualification, environmental monitoring classification, batch release procedures, and the Qualified Person (QP) certification requirement under EU law that has no direct FDA equivalent.

Step 4 — Analytical and Compendial Alignment: Map the lot release and characterization testing package against Ph. Eur. monographs applicable to ATMPs, confirm that identity assays using CD marker panels are documented in a format that addresses both CBER and EMA CAT expectations, and verify that the potency assay — whether cytolytic killing assay, cytokine release (IFN-γ, IL-2, TNF-α), or surrogate — is qualified to a standard that satisfies both agencies’ mechanism-of-action-based requirements.

The output of the XGene Cell Therapy Dual-Region CMC Gap Assessment is a jurisdiction-mapped CMC requirements matrix with close-out documentation assignments — not a list of deficiencies, but a structured remediation plan that identifies which existing documents satisfy both frameworks, which require bilateral expansion, and which require new documentation built specifically for the EU submission.

The cost of discovering a dual-region CMC gap at Day 180 of a CAT review is measured not only in the time required to remediate the deficiency, but in the clinical timeline disruption, the regulatory relationship damage with EMA, and the competitive exposure created when a program that could have been in EU clinical trials is delayed by documentation failures that have nothing to do with the product’s science or its safety profile. Programs that build their CMC packages with a single-jurisdiction architecture and attempt bilateral adaptation at the submission stage consistently underestimate the structural nature of the EU-specific requirements — not because they lack regulatory sophistication, but because the differences between CBER and EMA CAT are not visible in the overlapping ICH-harmonized sections where most CMC effort is concentrated. The traceability requirement, the GMP standard gap, the donor testing panel, and the ATMP classification confirmation are all pre-submission decisions — and they are all recoverable before first regulatory interaction if the gap assessment is conducted early enough to inform the program architecture.

If your cell therapy program plans both FDA and EMA submissions, can you identify today whether your starting material documentation satisfies EU Annex I Part IV requirements (not just 21 CFR 1271), whether your donor testing panel was assessed against EU Directive 2004/23/EC requirements, and whether your traceability system addresses the 30-year EU retention requirement?